A leading provider of
innovative DNA Screening solutions
PDGFB Breakapart Probe LPH031 - Detail
Some cases of Chronic Myelomonocytic Leukaemia (CML) have constitutive activation of the gene for PDGFRB (platelet derived growth factor receptor beta) which encodes a receptor for tyrosine kinase1. The activation is usually caused by a t(5;12)(q32;p13) translocation which results in the ETV6-PDGFRB fusion gene. The drug imatinib mesylate (Gleevec) specifically inhibits the kinase activity of PDGFRB and has shown efficiency in the treatment of chronic myeloid leukaemia and gastrointestinal stromal tumours. The breakpoint in PDGFRB is characteristically located in intron 102. It is located 10.7kb from the end of the gene.
Reference:/Bibliographie/Literatur/Bibliografia
- Apperley JF et al (2002) N Engl J Med 347: 481-487
- Tokita K et al (2007) Leukemia 21: 190-192
PDGFRB Breakapart Probe
Cat. No. LPH 031-S (5 tests)
Cat. No. LPH 031 (10 tests)
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK